These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 31265074)

  • 21. Case report: pembrolizumab-induced Type 1 diabetes in a patient with metastatic cholangiocarcinoma.
    Smith-Cohn MA; Gill D; Voorhies BN; Agarwal N; Garrido-Laguna I
    Immunotherapy; 2017 Sep; 9(10):797-804. PubMed ID: 28877632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
    Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
    JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased risk of immune checkpoint inhibitor-induced type 1 diabetes mellitus with the new approved 6-week scheme of pembrolizumab in patients with melanoma?
    Kähler KC; Kosova K; Bohne AS; Schreiber S; Hauschild A
    Eur J Cancer; 2020 Oct; 138():169-171. PubMed ID: 32890812
    [No Abstract]   [Full Text] [Related]  

  • 24. Uveal Effusion After Immune Checkpoint Inhibitor Therapy.
    Thomas M; Armenti ST; Ayres MB; Demirci H
    JAMA Ophthalmol; 2018 May; 136(5):553-556. PubMed ID: 29677240
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rapid onset type-1 diabetes and diabetic ketoacidosis secondary to nivolumab immunotherapy: a review of existing literature.
    Abdullah HMA; Elnair R; Khan UI; Omar M; Morey-Vargas OL
    BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31451458
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum concentrations of HGF are correlated with response to anti-PD-1 antibody therapy in patients with metastatic melanoma.
    Kubo Y; Fukushima S; Inamori Y; Tsuruta M; Egashira S; Yamada-Kanazawa S; Nakahara S; Tokuzumi A; Miyashita A; Aoi J; Kajihara I; Tomita Y; Wakamatsu K; Jinnin M; Ihn H
    J Dermatol Sci; 2019 Jan; 93(1):33-40. PubMed ID: 30318169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fulminant type 1 diabetes mellitus associated with pembrolizumab.
    Mizab Mellah C; Sánchez Pérez M; Santos Rey MD; Hernández García M
    Endocrinol Diabetes Nutr; 2017 May; 64(5):272-273. PubMed ID: 29056250
    [No Abstract]   [Full Text] [Related]  

  • 28. A Patient with Nivolumab-related Fulminant Type 1 Diabetes Mellitus whose Serum C-peptide Level Was Preserved at the Initial Detection of Hyperglycemia.
    Yamamoto N; Tsurutani Y; Katsuragawa S; Kubo H; Sunouchi T; Hirose R; Hoshino Y; Ichikawa M; Takiguchi T; Yukawa H; Arioka H; Saitou J; Nishikawa T
    Intern Med; 2019 Oct; 58(19):2825-2830. PubMed ID: 31243198
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.
    Kreft S; Gesierich A; Eigentler T; Franklin C; Valpione S; Ugurel S; Utikal J; Haferkamp S; Blank C; Larkin J; Garbe C; Schadendorf D; Lorigan P; Schilling B
    Eur J Cancer; 2019 Jul; 116():207-215. PubMed ID: 31212163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma.
    Rodriguez EF; Lipson E; Suresh K; Cappelli LC; Monaco SE; Maleki Z
    Hum Pathol; 2019 Sep; 91():69-76. PubMed ID: 31279873
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Onset of fulminant type 1 diabetes mellitus following hypophysitis after discontinuation of combined immunotherapy. A case report.
    Boswell L; Casals G; Blanco J; Jiménez A; Aya F; de Hollanda A; Halperin I; Arance AM; Mora M; Hanzu FA
    J Diabetes Investig; 2021 Dec; 12(12):2263-2266. PubMed ID: 34048145
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review.
    de Filette JMK; Pen JJ; Decoster L; Vissers T; Bravenboer B; Van der Auwera BJ; Gorus FK; Roep BO; Aspeslagh S; Neyns B; Velkeniers B; Kharagjitsingh AV
    Eur J Endocrinol; 2019 Sep; 181(3):363-374. PubMed ID: 31330498
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology Group.
    Grimmelmann I; Momma M; Zimmer L; Hassel JC; Heinzerling L; Pföhler C; Loquai C; Ruini C; Utikal J; Thoms KM; Kähler KC; Eigentler T; Herbst RA; Meier F; Debus D; Berking C; Kochanek C; Ugurel S; Gutzmer R;
    Eur J Cancer; 2021 May; 149():1-10. PubMed ID: 33812141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors.
    Mazarico I; Capel I; Giménez-Palop O; Albert L; Berges I; Luchtenberg F; García Y; Fernández-Morales LA; De Pedro VJ; Caixàs A; Rigla M
    J Endocrinol Invest; 2019 Dec; 42(12):1443-1450. PubMed ID: 31093955
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Checkpoint inhibitor treatment induces an increase in HbA1c in nondiabetic patients.
    Gauci ML; Boudou P; Squara PA; Delyon J; Allayous C; Mourah S; Resche-Rigon M; Lebbé C; Baroudjian B; Gautier JF;
    Melanoma Res; 2019 Jun; 29(3):328-332. PubMed ID: 30817442
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune Checkpoint Inhibitor-Induced Diabetic Ketoacidosis: A Report of Four Cases and Literature Review.
    Hong AR; Yoon JH; Kim HK; Kang HC
    Front Endocrinol (Lausanne); 2020; 11():14. PubMed ID: 32047478
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A case of pembrolizumab-induced fulminant Type 1 diabetes mellitus in breast cancer.
    Tang Y; Zhao Z; Wang X; Zuo W; Zhang B; Yuan T; Fu Y
    Immunotherapy; 2021 Apr; 13(6):483-489. PubMed ID: 33626915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy.
    Okamoto M; Okamoto M; Gotoh K; Masaki T; Ozeki Y; Ando H; Anai M; Sato A; Yoshida Y; Ueda S; Kakuma T; Shibata H
    J Diabetes Investig; 2016 Nov; 7(6):915-918. PubMed ID: 27181090
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination therapy of ipilimumab and nivolumab induced thyroid storm in a patient with Hashimoto's disease and diabetes mellitus: a case report.
    Yonezaki K; Kobayashi T; Imachi H; Yoshimoto T; Kikuchi F; Fukunaga K; Sato S; Ibata T; Yamaji N; Lyu J; Dong T; Murao K
    J Med Case Rep; 2018 Jun; 12(1):171. PubMed ID: 29914537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes.
    Kotwal A; Haddox C; Block M; Kudva YC
    BMJ Open Diabetes Res Care; 2019; 7(1):e000591. PubMed ID: 30899528
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.